Dynamics of coagulopathy in patients with different COVID-19 severity.

COVID-19 endothelial function plasma coagulation platelet aggregation

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
04 Jul 2020
Historique:
pubmed: 9 7 2020
medline: 9 7 2020
entrez: 9 7 2020
Statut: epublish

Résumé

With the progress of COVID-19 studies, it became evident that SARS-CoV-2 infection is often associated with thrombotic complications. The goal of our present study was to evaluate which component of clot formation process including endothelial function, platelets aggregation and plasma coagulation, as well as endogenous fibrinolysis in patients with COVID-19 correlates with the severity of the disease. We prospectively included 58 patients with COVID-19 and 47 healthy volunteers as a control group that we recruited before the pandemic started. It turns out that plasma coagulation with subsequent platelet aggregation, but not endothelial function, correlates with the severity of the COVID-19. IL-6 blockade may play a beneficial role in COVID-19 induced coagulopathy.

Identifiants

pubmed: 32637973
doi: 10.1101/2020.07.02.20145284
pmc: PMC7340199
pii:
doi:

Types de publication

Preprint

Langues

eng

Déclaration de conflit d'intérêts

Conflict of interest The authors have declared that no conflict of interest exists.

Auteurs

Anna Kalinskaya (A)

Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia.
Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Oleg Dukhin (O)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Ivan Molodtsov (I)

Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia.

Alexandra Maltseva (A)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Denis Sokorev (D)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Antonina Elizarova (A)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Olga Sapozhnikova (O)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Ksenia Glebova (K)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Daria Stonogina (D)

Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Soslan Shakhidzhanov (S)

Center for Theoretical Problems of Physico-Chemical Pharmacology RAS, Moscow, Russia.

Evgeniy Nikonov (E)

Pirogov Russian National Research Medical University, Moscow, Russia.

Alexey Mazus (A)

Moscow City Center for AIDS Prevention and Control, Moscow Department of Healthcare, Moscow, Russia.

Ilia Spiridonov (I)

Center for Theoretical Problems of Physico-Chemical Pharmacology RAS, Moscow, Russia.

Fazly Ataullakhanov (F)

Center for Theoretical Problems of Physico-Chemical Pharmacology RAS, Moscow, Russia.
University of Pennsylvania, Philadelphia, USA.

Leonid Margolis (L)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA.

Alexander Shpektor (A)

Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia.
Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Elena Vasilieva (E)

Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare, Moscow, Russia.
Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Classifications MeSH